Kumar Rajesh, Salwe Kartik Janardan, Kumarappan Manimekalai
Medical Advisor, Medical Affairs, GlaxoSmithKline Pharmaceuticals Limited, Bengaluru, Karnataka, India.
Department of Pharmacology, Mahatma Gandhi Medical College and Research Institute, Puducherry, India.
Pharmacognosy Res. 2017 Apr-Jun;9(2):161-167. doi: 10.4103/0974-8490.204654.
Atherosclerosis is one of the major causes of morbidity and mortality in the world. Antioxidants play a major role in prophylaxis and prevention of progression and complications of atherosclerosis.
In this study, we are evaluating the antiatherosclerotic effect of two antioxidants such as astaxanthin and lycopene.
After acclimatization, 24 male SD rats, 8-10 weeks old, 150 ± 10 g, maintained as per CPCSEA guidelines were divided into four groups of six rats each. Baseline values of weight lipid profile and 2-Thiobarbituric Acid Reactive Substances (TBARS) assay were taken. All the rats were fed with high cholesterol diet (HCD). HCD only, HCD + atorvastatin (50 mg/kg), HCD + lycopene (50 mg/kg), and HCD + astaxanthin (50 mg/kg) were given to control, standard, lycopene, and astaxanthin groups, respectively, through oral gavage for 45 days. The rats were sacrificed at the end of the study, blood sample collected from aorta, and then aorta was dissected for histopathology.
The lipid profile showed lycopene and astaxanthin decreased total cholesterol, low-density lipoprotein-cholesterol (LDL-C), very LDL-C, and triglycerides and increased high-density lipoprotein-cholesterol level significantly ( < 0.05) compared to the control but less than atorvastatin. The TBARS value of lycopene was significantly lower compared to HCD and atorvastatin groups, whereas astaxanthin was significantly less than HCD group only. The histopathology showed only Type I lesions, no naked fatty streaks, few foam cells in lycopene, and astaxanthin groups compared to control where we observed Type II and III lesions, visible fatty streaks and many foam cells with intimal thickening in HCD group.
In this study, lycopene and astaxanthin showed antioxidant, antihyperlipidemic, and antiatherosclerotic property. This warrants further study for including them in the treatment of atherosclerosis.
Antioxidants play a major role in prophylaxis and prevention of progression and complications of atherosclerosis.Lycopene and Astaxanthin are suitable candidates for further research in cardiovascular disease and there is paucity of studies evaluating their role in prevention of atherosclerosis.The effect of lycopene and Astaxanthin for anti-atherosclerotic property was evaluated in high cholesterol diet fed rats.The lipid profile showed lycopene and Astaxanthin decreased TC, LDL-C, VLDL-C and triglycerides and increased HDL-C level significantly ( < 0.05) compared to the control but less than atorvastatin.The TBARS value of Lycopene was significantly lower compared to HCD and atorvastatin groups while Astaxanthin was significantly less than HCD group only.The histopathology showed only type I lesions, no naked fatty streaks, few foam cells in lycopene and Astaxanthin groups compared to control.The study proves Lycopene and Astaxanthin have hypolipideamic and anti-atherogenic potential can be included in the treatment of hypercholesterolemia and atherosclerosis. TC: total cholesterol, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, VLDL-C: very Low density lipoprotein cholesterol, TG: triglycerides, and TBARS: thiobarbituric acid reactive substances, HCD: high cholesterol diet.
动脉粥样硬化是全球发病和死亡的主要原因之一。抗氧化剂在动脉粥样硬化的预防、进展及并发症的防治中发挥着重要作用。
在本研究中,我们评估虾青素和番茄红素这两种抗氧化剂的抗动脉粥样硬化作用。
适应环境后,将24只8 - 10周龄、体重150±10克的雄性SD大鼠按照CPCSEA指南进行饲养,并分为四组,每组6只。记录体重、血脂谱和2-硫代巴比妥酸反应物质(TBARS)检测的基线值。所有大鼠均喂食高胆固醇饮食(HCD)。分别通过灌胃法给予对照组HCD、标准组HCD +阿托伐他汀(50毫克/千克)、番茄红素组HCD +番茄红素(50毫克/千克)和虾青素组HCD +虾青素(50毫克/千克),持续45天。在研究结束时处死大鼠,从主动脉采集血样,然后解剖主动脉进行组织病理学检查。
血脂谱显示,与对照组相比,番茄红素和虾青素显著降低了总胆固醇、低密度脂蛋白胆固醇(LDL-C)、极低密度脂蛋白胆固醇(VLDL-C)和甘油三酯水平,并显著提高了高密度脂蛋白胆固醇水平(P<0.05),但低于阿托伐他汀。与HCD组和阿托伐他汀组相比,番茄红素的TBARS值显著降低,而虾青素仅显著低于HCD组。组织病理学显示,与对照组相比,番茄红素组和虾青素组仅出现I型病变,无明显脂肪条纹,仅有少量泡沫细胞,而对照组观察到II型和III型病变,有明显脂肪条纹和许多泡沫细胞,且内膜增厚。
在本研究中,番茄红素和虾青素表现出抗氧化、降血脂和抗动脉粥样硬化特性。这值得进一步研究以将它们纳入动脉粥样硬化的治疗。
抗氧化剂在动脉粥样硬化的预防、进展及并发症的防治中发挥着重要作用。番茄红素和虾青素是心血管疾病进一步研究的合适候选物,且评估它们在预防动脉粥样硬化中作用的研究较少。在喂食高胆固醇饮食的大鼠中评估了番茄红素和虾青素的抗动脉粥样硬化特性。血脂谱显示,与对照组相比,番茄红素和虾青素显著降低了总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、极低密度脂蛋白胆固醇(VLDL-C)和甘油三酯水平,并显著提高了高密度脂蛋白胆固醇(HDL-C)水平(P<0.05),但低于阿托伐他汀。与HCD组和阿托伐他汀组相比,番茄红素的TBARS值显著降低,而虾青素仅显著低于HCD组。组织病理学显示,与对照组相比,番茄红素组和虾青素组仅出现I型病变,无明显脂肪条纹,仅有少量泡沫细胞。该研究证明番茄红素和虾青素具有降血脂和抗动脉粥样硬化潜力,可纳入高胆固醇血症和动脉粥样硬化的治疗。TC:总胆固醇,HDL-C:高密度脂蛋白胆固醇,LDL-C:低密度脂蛋白胆固醇,VLDL-C:极低密度脂蛋白胆固醇,TG:甘油三酯,TBARS:硫代巴比妥酸反应物质,HCD:高胆固醇饮食